title: Elevated free fatty acids impair glucose metabolism in women: decreased stimulation of muscle glucose uptake and suppression of splanchnic glucose production during combined hyperinsulinemia and hyperglycemia.
abstract: The present study sought to determine whether elevated plasma free fatty acids (FFAs) alter the splanchnic and muscle glucose metabolism in women. To do so, FFAs were increased in seven women by an 8-h Intralipid/heparin (IL/hep) infusion, and the results were compared with those observed in nine women who were infused with glycerol alone. Glucose was clamped at approximately 8.3 mmol/l and insulin was increased to approximately 300 pmol/l to stimulate both muscle and hepatic glucose uptake. Insulin secretion was inhibited with somatostatin. Leg and splanchnic glucose metabolism were assessed using a combined catheter and tracer dilution approach. The glucose infusion rates required to maintain target plasma glucose concentrations were lower (P < 0.01) during IL/hep than glycerol infusion (30.8 +/- 2.6 vs. 65.0 +/- 7.9 micro mol. kg(-1). min(-1)). Whole-body glucose disappearance (37.0 +/- 2.2 vs. 70.9 +/- 8.7 micro mol. kg(-1). min(-1); P < 0.001) and leg glucose uptake (24.3 +/- 4.2 vs. 59.6 +/- 10.0 micro mol. kg fat-free mass of the leg(-1). min(-1); P < 0.02) were also lower, whereas splanchnic glucose production (8.2 +/- 0.8 vs. 4.3 +/- 0.7 micro mol. kg(-1). min(-1); P < 0.01) was higher during IL/hep than glycerol infusion. We conclude that in the presence of combined hyperinsulinemia and hyperglycemia, elevated FFAs impair glucose metabolism in women by inhibiting whole- body glucose disposal, muscle glucose uptake, and suppression of splanchnic glucose production.
authors.affiliation: Endocrine Research Unit, Mayo Clinic, Rochester, Minnesota 55905, USA.
authors.forename: Pankaj
authors.initials: P
authors.lastname: Shah
authors.forename: Adrian
authors.initials: A
authors.lastname: Vella
authors.forename: Ananda
authors.initials: A
authors.lastname: Basu
authors.forename: Rita
authors.initials: R
authors.lastname: Basu
authors.forename: Aron
authors.initials: A
authors.lastname: Adkins
authors.forename: W Frederick
authors.initials: WF
authors.lastname: Schwenk
authors.forename: C Michael
authors.initials: CM
authors.lastname: Johnson
authors.forename: K Sreekumaran
authors.initials: KS
authors.lastname: Nair
authors.forename: Michael D
authors.initials: MD
authors.lastname: Jensen
authors.forename: Robert A
authors.initials: RA
authors.lastname: Rizza
mesh_terms: D000328:Adult; D002096:C-Peptide / Q000097:blood; D005230:Fatty Acids, Nonesterified / Q000097:blood*; D005260:Female; D005947:Glucose / Q000008:administration & dosage / Q000378:metabolism* / Q000493:pharmacokinetics / Q000494:pharmacology; D005990:Glycerol / Q000097:blood; D019382:Human Growth Hormone / Q000097:blood; D006801:Humans; D006943:Hyperglycemia / Q000150:complications / Q000378:metabolism*; D006946:Hyperinsulinism / Q000150:complications / Q000378:metabolism*; D007866:Leg; D018482:Muscle, Skeletal / Q000378:metabolism*; D014781:Viscera / Q000378:metabolism*
chemical_list: D002096:C-Peptide; D005230:Fatty Acids, Nonesterified; D019382:Human Growth Hormone; D005947:Glucose; D005990:Glycerol